Search results
Added:
1 year ago
HFSA 2024 - We are joined by Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) to discuss the findings from HuMAIN HFpEF, a phase 2A randomized, parallel-group, placebo-controlled study of HU6 in patients with obesity and heart failure with preserved ejection fraction (HFpEF).Interview Questions:What is the reasoning behind this study?Could you tell us about the mechanism…
View more
Added:
7 months ago
This webinar series, recorded at the ESC 2025 with key opinion leaders Dr David Berg (Brigham and Women's Hospital, Boston, US) and Dr Clara Saldarriaga (Cardio VID Clinic, Medellin, CO) presenting late-breaking data, explores the evolving evidence for in-hospital initiation of guideline-directed medical therapy after an acute heart failure event. Viewers will gain insight into the persistent…
View more
Added:
7 months ago
ESC Congress 2025 - The opening day of ESC Congress 2025 delivered compelling new developments as updated clinical practice guidelines were released alongside a series of eagerly awaited Hot Line trials.Leading interventional cardiologists, Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (The King Fahd Armed Forces Hospital, SA) present focused overviews of the most significant Hot Line and Late…
View more
Precision in Practice
Start date:
May 17, 2025
End date:
May 17, 2025
Event
Added:
1 month ago
Source:
Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,…
View more
Added:
1 year ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What…
View more
Added:
1 year ago
ESC Congress — Ms Carys Barton (Imperial College Healthcare NHS Trust, London, UK) joins us on-site to talk about the implementation of heart failure guidelines.Interview Questions:1. What are the biggest challenges in implementing heart failure guidelines?2. How do nurses help implement guidelines, and what strategies do they use?3. What training can help with guideline implementation?4. How can…
View more
Added:
8 months ago
Source:
Radcliffe Cardiology
A new meta-analysis suggests that the more time an individual's ambulatory blood pressure (ABP) is within the target range proposed by the 2024 European Society of Cardiology (ESC) guidelines, the lower their risk of mortality and cardiovascular events.¹ The findings also highlight that office blood pressure measurements frequently misclassify patients with regard to their actual blood pressure…
View more
Added:
1 year ago
Join renowned interventional cardiologists Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) for an exclusive preview of ACC.25's most significant late-breaking science.This episode of View from the Thoraxcenter delivers authoritative analysis of pivotal cardiovascular trials set to revolutionize clinical practice and research. Elevate your conference…
View more
Added:
1 week ago
Source:
CFR Journal
Consumer wearable devices may offer a scalable method for the daily monitoring of heart failure (HF) symptoms and predicting exacerbations. A new study has detailed how a deep learning model using Apple Watch data can estimate cardiopulmonary fitness and provide early risk discrimination for unplanned healthcare events in patients with HF.¹MethodologyThe Ted Rogers Understanding Exacerbations of…
View more